Counterfeit protection with efficient barcode capture

The labelling of medical products poses challenges for players in the supply chain. Zetes offers efficient barcode capture.

The EU Falsified Medicines Directive (FMD) has been in force since February 2019. Products in the medical supply chain must be labelled with a 2D barcode and display different product data. Zetes looks at the challenges this poses for various stakeholders. 

The FMD is intended to prevent counterfeit products from entering the medical supply chain. This applies to counterfeit medicines, but also to false data on products regarding the source of a medicine. Special labelling and marking are required, which is necessary for operational inefficiencies when large quantities are decommissioned or checked must. Zetes suggests the simultaneous capture of several barcodes as a solution.

Customers are looking for a more efficient way to capture serial numbers, which is labour intensive and time consuming when done by manually scanning one box of medicine at a time. For its many customers, the company has developed a portfolio of ImageID workstations that Machine vision and algorithms for fast decoding of multiple data matrix codes on medicine packaging combine.

Operators can make lists of the serial numbers of the goods in each container/pallet for picking by the FMD solution or use them to create aggregation files that are sent via a secure and controlled process to hospitals where picking can be initiated.

Display

"There are parts of the supply chain where the number of units to be scanned is very high, resulting in a high workload for operators and operational inefficiency. Zetes FMD traceability is tailored to specific needs and is available in both a retailer and hospital version to provide each actor with the most efficient solution according to their rights and obligations under the Directive."

Jean-Pierre MoulyGroup Business Consultant at Zetes

Source: Zetes

Picture of a man.
Jean-Pierre Mouly (Image: Zetes)

Further news from the pharma sector